Analysts expect that Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) will post ($1.00) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have provided estimates for Rhythm Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.91) and the lowest estimate coming in at ($1.08). Rhythm Pharmaceuticals posted earnings of ($0.79) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 26.6%. The business is expected to issue its next quarterly earnings results on Monday, March 7th.
On average, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($1.38) per share for the current fiscal year, with EPS estimates ranging from ($1.45) to ($1.31). For the next fiscal year, analysts forecast that the business will report earnings of ($3.34) per share, with EPS estimates ranging from ($3.37) to ($3.32). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings results on Tuesday, November 2nd. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.13. The company had revenue of $1.03 million for the quarter. During the same quarter last year, the business posted ($0.77) EPS.
Shares of NASDAQ RYTM opened at $9.03 on Friday. The firm’s 50-day simple moving average is $10.53 and its 200 day simple moving average is $13.52. The company has a market cap of $453.92 million, a price-to-earnings ratio of -7.00 and a beta of 1.31. Rhythm Pharmaceuticals has a 12-month low of $8.33 and a 12-month high of $43.26.
Several large investors have recently made changes to their positions in the stock. Moors & Cabot Inc. acquired a new stake in shares of Rhythm Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Bank of New York Mellon Corp raised its position in shares of Rhythm Pharmaceuticals by 11.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 156,423 shares of the company’s stock valued at $2,043,000 after acquiring an additional 16,391 shares during the period. BNP Paribas Arbitrage SA raised its position in shares of Rhythm Pharmaceuticals by 105.9% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 10,908 shares of the company’s stock valued at $142,000 after acquiring an additional 5,611 shares during the period. UBS Group AG raised its position in shares of Rhythm Pharmaceuticals by 1.1% in the 3rd quarter. UBS Group AG now owns 80,970 shares of the company’s stock valued at $1,058,000 after acquiring an additional 851 shares during the period. Finally, Rock Springs Capital Management LP raised its position in shares of Rhythm Pharmaceuticals by 1.0% in the 3rd quarter. Rock Springs Capital Management LP now owns 612,180 shares of the company’s stock valued at $7,995,000 after acquiring an additional 5,900 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.